Equity Profile

KOD

Kodiak Sciences Inc.

Health CareBiotechnology$2.6B

Aug12Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Kodiak Sciences Inc. is a biotechnology company focused on developing innovative therapies for eye diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is crucial for understanding the company's profitability and financial health.

N/A

Revenue Growth

Revenue growth indicates the company's ability to expand its market presence and product adoption.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

KOD Q2-2026 Earnings Preview

Context

Company Snapshot

Kodiak Sciences Inc. is a biotechnology company focused on developing innovative therapies for eye diseases. As part of the health care sector, its advancements could significantly impact treatment options for conditions like diabetic macular edema and retinal diseases.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-3.44%

Avg Stock Reaction

-0.51%

Last Quarter Recap

In Q1-2026, Kodiak reported an EPS of -$0.94, slightly missing estimates. The stock reacted negatively, declining by 4.82% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations are mixed as Kodiak has struggled with earnings surprises in recent quarters. Investors are looking for signs of improvement in both EPS and revenue.

Bull Case

If Kodiak can show significant progress in its clinical trials and improve its EPS, it could regain investor confidence and drive the stock higher.

Bear Case

Continued losses and lack of revenue growth could lead to further declines in stock price, especially if the company fails to meet market expectations.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the latest update on clinical trial results for Kodiak's lead drug candidate?

Positive trial results could significantly boost investor confidence and stock price.

How does Kodiak plan to address its ongoing losses and improve its revenue streams?

Investors will be keen to hear a clear strategy for returning to profitability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Kodiak's potential for a turnaround due to its innovative drug pipeline, which could lead to unexpected revenue growth.

Supporting Evidence

The options market is pricing in a 39.1% move, suggesting traders anticipate significant volatility.

Kodiak's previous earnings reactions show a pattern of recovery after initial misses, indicating potential for rebound.

Key Risk

If clinical trial results exceed expectations, it could shift the narrative and drive the stock higher.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's focus will be on whether Kodiak can demonstrate progress in its clinical trials and improve its financial outlook.

Bull Confirmed If

A reduction in EPS losses to below -$0.80 could confirm a turnaround in financial performance.

Bear Confirmed If

If EPS remains above -$1.00 without any revenue growth, it would confirm ongoing financial struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±39.1%

Historical Avg

±4.5%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings report.

Options are pricing ±39.1% while KOD has averaged ±4.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

60.4%

Calls (22K)P/C Ratio: 0.43Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Kodiak beats expectations, history suggests the stock could rise by an average of 1.5%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await clearer guidance.

Miss

Should Kodiak miss expectations, history indicates a potential decline of around 0.1%, reinforcing bearish sentiment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the timeline for clinical trial results.
2Any commentary on partnerships or collaborations that may enhance revenue.
3Insights into cost management strategies to reduce losses.
4Details on market expansion plans and product launches.
5Management's outlook on the competitive landscape in the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug10

BWBMO

Babcock & Wilcox Enterprises, Inc.

PreviewView

Aug10

ROIVBMO

Company Snapshot

Kodiak Sciences Inc. is a biotechnology company focused on developing innovative therapies for eye diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is crucial for understanding the company's profitability and financial health.

N/A

Revenue Growth

Revenue growth indicates the company's ability to expand its market presence and product adoption.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

KOD Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-3.44%

Avg Stock Reaction

-0.51%

Last Quarter Recap

In Q1-2026, Kodiak reported an EPS of -$0.94, slightly missing estimates. The stock reacted negatively, declining by 4.82% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations are mixed as Kodiak has struggled with earnings surprises in recent quarters. Investors are looking for signs of improvement in both EPS and revenue.

Bull Case

If Kodiak can show significant progress in its clinical trials and improve its EPS, it could regain investor confidence and drive the stock higher.

Bear Case

Continued losses and lack of revenue growth could lead to further declines in stock price, especially if the company fails to meet market expectations.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the latest update on clinical trial results for Kodiak's lead drug candidate?

Positive trial results could significantly boost investor confidence and stock price.

How does Kodiak plan to address its ongoing losses and improve its revenue streams?

Investors will be keen to hear a clear strategy for returning to profitability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Kodiak's potential for a turnaround due to its innovative drug pipeline, which could lead to unexpected revenue growth.

Supporting Evidence

The options market is pricing in a 39.1% move, suggesting traders anticipate significant volatility.

Kodiak's previous earnings reactions show a pattern of recovery after initial misses, indicating potential for rebound.

Key Risk

If clinical trial results exceed expectations, it could shift the narrative and drive the stock higher.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's focus will be on whether Kodiak can demonstrate progress in its clinical trials and improve its financial outlook.

Bull Confirmed If

A reduction in EPS losses to below -$0.80 could confirm a turnaround in financial performance.

Bear Confirmed If

If EPS remains above -$1.00 without any revenue growth, it would confirm ongoing financial struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±39.1%

Historical Avg

±4.5%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings report.

Options are pricing ±39.1% while KOD has averaged ±4.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

60.4%

Calls (22K)P/C Ratio: 0.43Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Kodiak beats expectations, history suggests the stock could rise by an average of 1.5%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await clearer guidance.

Miss

Should Kodiak miss expectations, history indicates a potential decline of around 0.1%, reinforcing bearish sentiment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the timeline for clinical trial results.
2Any commentary on partnerships or collaborations that may enhance revenue.
3Insights into cost management strategies to reduce losses.
4Details on market expansion plans and product launches.
5Management's outlook on the competitive landscape in the biotechnology sector.